Rubius Therapeutics, Inc. (RUBY) Stock Analysis
DELISTED 2023
What happened to Rubius Therapeutics, Inc. (RUBY) stock?
Rubius Therapeutics, Inc. (RUBY) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rubius Therapeutics, Inc. (RUBY) trades at $0.057. Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing red cell therapeutics (RCTs) for severe diseases. Their pipeline includes RCTs targeting solid tumors, HPV-positive tumors, and type 1 diabetes. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for RUBY: RUBY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RUBY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
RUBY: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Rubius Therapeutics, Inc. (RUBY) Healthcare & Pipeline Overview
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering red cell therapeutics (RCTs) for cancer and autoimmune diseases. With a focus on allogeneic cellular therapies, Rubius aims to address unmet needs in oncology and other severe conditions, operating within the competitive biotechnology landscape.
What Is the Investment Thesis for RUBY?
Rubius Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's red cell therapeutics (RCTs) platform offers a novel approach to treating cancer and autoimmune diseases. Key value drivers include the clinical progress of RTX-240 and RTX-224 in solid tumors, with potential data readouts expected in the next 12-18 months. Successful clinical trials and regulatory approvals could significantly increase the company's valuation. However, the company's limited financial resources and dependence on clinical trial outcomes pose significant risks. The company's small size, with only 6 employees, also presents operational challenges. Investors should closely monitor clinical trial results, regulatory developments, and the company's cash runway.
Based on FMP financials and quantitative analysis
RUBY Key Highlights
Rubius Therapeutics is a clinical-stage biopharmaceutical company focused on red cell therapeutics (RCTs).
- The company's lead product candidates, RTX-240 and RTX-224, are in development for the treatment of solid tumors.
- Rubius is also developing RCTs for HPV-positive tumors (RTX-321) and type 1 diabetes (RTX-T1D).
- The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
- Rubius Therapeutics employs 6 people.
Who Are RUBY's Competitors?
RUBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RUBY's Key Strengths?
Novel red cell therapeutics (RCTs) platform.
- Focus on unmet medical needs in oncology and autoimmune diseases.
- Potential for safer and more effective therapies compared to traditional treatments.
- Experienced management team with expertise in cell-based therapies.
What Are RUBY's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources and dependence on clinical trial outcomes.
- Small company size with only 6 employees.
- High risk of clinical trial failures and regulatory setbacks.
What Could Drive RUBY Stock Higher?
Clinical trial data readouts for RTX-240 and RTX-224 in solid tumors.
- Commencement of clinical trials for RTX-T1D in type 1 diabetes.
- Potential strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancement of manufacturing capabilities to support clinical development and potential commercialization.
- Regulatory interactions and potential approvals for its RCT product candidates.
What Are the Key Risks for RUBY?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and regulatory setbacks.
- Difficulty in raising additional capital to fund research and development.
- Competition from established pharmaceutical companies and other biotech firms.
- Dependence on the success of its red cell therapeutics (RCTs) platform.
- Limited financial resources and small company size.
What Are the Growth Opportunities for RUBY?
- Expansion into New Oncology Indications: Rubius has the opportunity to expand its RCT platform into additional oncology indications beyond solid tumors. The global oncology market is projected to reach $286.6 billion by 2028, offering a substantial market opportunity. By leveraging its existing technology and clinical data, Rubius can develop new RCT product candidates targeting specific cancer types with unmet medical needs. This expansion could involve strategic partnerships or internal development programs, with potential clinical trials commencing within the next 2-3 years.
- Advancement of Autoimmune Disease Programs: Rubius's RTX-T1D program for type 1 diabetes represents a significant growth opportunity in the autoimmune disease market. The global autoimmune disease market is estimated at $127.77 billion in 2024 and is expected to grow. Positive preclinical and clinical data for RTX-T1D could lead to partnerships with larger pharmaceutical companies or further internal development. Clinical trials for RTX-T1D could commence within the next 1-2 years, providing a potential catalyst for growth.
- Strategic Partnerships and Collaborations: Rubius can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its RCT platform. These partnerships could provide access to additional funding, expertise, and resources. Collaborations could focus on specific indications or the broader development of the RCT platform. Successful partnerships could be established within the next 12-18 months, leading to increased investor confidence and potential revenue streams.
- Expansion of Manufacturing Capabilities: As Rubius's clinical programs advance, the company will need to expand its manufacturing capabilities to meet potential demand. Investing in scalable and cost-effective manufacturing processes is crucial for long-term growth. This expansion could involve building internal manufacturing facilities or outsourcing to contract manufacturing organizations (CMOs). Decisions regarding manufacturing expansion are likely to occur within the next 2-3 years, depending on clinical trial progress.
- Securing Regulatory Approvals: Obtaining regulatory approvals for its RCT product candidates is a critical growth driver for Rubius. Successful clinical trials and positive regulatory reviews are essential for commercializing its therapies. The FDA and other regulatory agencies will evaluate the safety and efficacy of Rubius's RCTs. Regulatory decisions are expected within the next 2-4 years, depending on the specific product candidate and clinical trial timelines.
What Are RUBY's Competitive Advantages?
- Proprietary red cell therapeutics (RCTs) platform.
- Intellectual property protection for its technology and product candidates.
- Novel approach to cellular therapy with potential advantages over existing treatments.
- Expertise in genetic engineering and cell-based therapies.
What Does RUBY Do?
Rubius Therapeutics, Inc., founded in 2013 and headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of severe diseases through its innovative red cell therapeutics (RCTs) platform. The company's core technology leverages the unique properties of red blood cells to create allogeneic cellular therapies designed to stimulate or suppress the immune system. Rubius is developing a pipeline of RCT product candidates targeting various oncology and autoimmune indications. Key programs include RTX-240 and RTX-224, which are being developed for the treatment of solid tumors. RTX-aAPC is another program targeting cancers. Additionally, the company is advancing RTX-321 for HPV-positive tumors and RTX-T1D for type 1 diabetes. Rubius's approach involves genetically engineering red blood cells to express therapeutic proteins on their surface, offering a potentially safer and more effective alternative to traditional therapies. The company's focus is on addressing significant unmet medical needs in areas where current treatment options are limited or inadequate. Rubius operates primarily in the United States, conducting research and development activities to advance its RCT platform and clinical programs.
What Products and Services Does RUBY Offer?
- Develop red cell therapeutics (RCTs) for severe diseases.
- Focus on allogeneic cellular therapies.
- Target oncology and autoimmune indications.
- Genetically engineer red blood cells to express therapeutic proteins.
- Conduct clinical trials to evaluate the safety and efficacy of RCTs.
- Seek regulatory approvals for its product candidates.
How Does RUBY Make Money?
- Develop and commercialize red cell therapeutics (RCTs).
- Generate revenue through product sales upon regulatory approval.
- Potentially generate revenue through strategic partnerships and collaborations.
- Fund research and development activities through venture capital and public offerings.
What Industry Does RUBY Operate In?
Rubius Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing incidence rates. The company's red cell therapeutics (RCTs) platform represents a novel approach within the broader field of immunotherapy. Competition includes established pharmaceutical companies and other biotech firms developing cell-based therapies. Success depends on demonstrating clinical efficacy and safety, navigating regulatory pathways, and securing sufficient funding.
Who Are RUBY's Key Customers?
- Patients with severe diseases, including cancer and autoimmune disorders.
- Healthcare providers who prescribe and administer Rubius's therapies.
- Hospitals and clinics that utilize Rubius's products.
- Potential pharmaceutical partners for collaborations and licensing agreements.
Company Profile
Rubius Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Laurence A. Turka. RUBY has traded publicly since 2018.
Financial Health
Rubius Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RUBY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel red cell therapeutics (RCTs) platform.
- Focus on unmet medical needs in oncology and autoimmune diseases.
- Potential for safer and more effective therapies compared to traditional treatments.
- Experienced management team with expertise in cell-based therapies.
Bear Case
- Clinical-stage company with no approved products.
- Limited financial resources and dependence on clinical trial outcomes.
- Small company size with only 6 employees.
- High risk of clinical trial failures and regulatory setbacks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RUBY Latest News
No recent news available for RUBY.
Leadership: Laurence A. Turka
Unknown
Laurence A. Turka serves as the leader of Rubius Therapeutics, overseeing the company's strategic direction and operations. His background likely includes extensive experience in the biotechnology or pharmaceutical industry, with a focus on drug development and commercialization. He likely holds advanced degrees in a relevant scientific field, such as biology or medicine, and has a proven track record of leading and managing teams in a research-intensive environment. His previous roles likely involved significant responsibilities in clinical development, regulatory affairs, and business development.
Track Record: Given the limited information available, Laurence A. Turka's track record at Rubius Therapeutics is difficult to assess comprehensively. However, his leadership is crucial in guiding the company through clinical trials and securing partnerships. His ability to navigate the regulatory landscape and raise capital will be critical to the company's success. The progress of Rubius's clinical programs and the company's financial performance will be key indicators of his effectiveness as CEO.
RUBY Healthcare Stock FAQ
What happened to Rubius Therapeutics, Inc. (RUBY) stock?
Rubius Therapeutics, Inc. (RUBY) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
Can I still buy RUBY shares?
No. RUBY stopped trading on public markets in December 2023, so the shares are not available through a broker. Anything you see quoted for RUBY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RUBY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Rubius Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Rubius Therapeutics, Inc. do?
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of red cell therapeutics (RCTs) for the treatment of severe diseases. Their core technology involves genetically engineering red blood cells to express therapeutic proteins on their surface, creating allogeneic cellular therapies. These therapies are designed to stimulate or suppress the immune system, targeting oncology and autoimmune indications.
What do analysts say about RUBY stock?
Given that Rubius Therapeutics has a small market capitalization and is a clinical-stage company, analyst coverage may be limited. Any analyst ratings and price targets should be viewed with caution, considering the inherent risks and uncertainties associated with biotechnology companies.
What are the main risks for RUBY?
Rubius Therapeutics faces several significant risks inherent to its business model and the biotechnology industry. Clinical trial failures represent a major risk, as the company's product candidates may not demonstrate sufficient safety or efficacy. Regulatory setbacks, such as delays or rejections of marketing applications, could also negatively impact the company's prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a clinical-stage biopharmaceutical company, and its future success depends on the outcome of clinical trials and regulatory approvals.